Covered recipient · General Payments record
AMRITA KRISHNAN
Allopathic & Osteopathic Physicians Internal Medicine Hematology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$83,995.08
58 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $44,875.00 | 17 |
| Consulting Fee | $25,795.00 | 10 |
| Honoraria | $8,075.00 | 3 |
| Travel and Lodging | $3,970.61 | 10 |
| Food and Beverage | $1,279.47 | 18 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GlaxoSmithKline, LLC. | $19,257.64 | 10 |
| E.R. Squibb & Sons, L.L.C. | $18,800.35 | 14 |
| GENZYME CORPORATION | $15,624.64 | 10 |
| Takeda Pharmaceuticals U.S.A., Inc. | $13,556.70 | 9 |
| PFIZER INC. | $9,020.00 | 4 |
| Adaptive Biotechnologies Corporation | $7,283.85 | 5 |
| Janssen Biotech, Inc. | $252.98 | 2 |
| Celgene Corporation | $184.68 | 3 |
| ABBVIE INC. | $14.24 | 1 |
Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
AMRITA KRISHNAN
NPI 1215948690 · CMS profile ID 100883
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology
DUARTE, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1215948690?year=2022&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- AMRITA KRISHNAN, NPI 1215948690, CMS profile ID 100883. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1215948690?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). AMRITA KRISHNAN, NPI 1215948690, CMS profile ID 100883. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1215948690?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- AMRITA KRISHNAN, NPI 1215948690, CMS profile ID 100883, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1215948690?year=2022&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
58 matching records · $83,995.08 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–58 of 58.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $1,570.00 | 03/10/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 955690987 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $785.00 | 02/17/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 955690983 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $785.00 | 02/11/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 955690979 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1,384.00 | 02/08/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932511887 | CMS |
| PFIZER INC. | $4,000.00 | 01/24/2022 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949352817 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1,800.00 | 01/13/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932511875 | CMS |
| PFIZER INC. | $1,575.00 | 01/06/2022 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949352939 | CMS |
| GENZYME CORPORATION | $729.00 | 01/01/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 938812141 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $948,287.79 | 59 |
| PY2024 | Recipient | $1,050.44 | 2 |
| PY2024 | Principal investigator | $1,690,121.58 | 68 |
| PY2023 | Principal investigator | $1,425,000.66 | 61 |
| PY2022 | Principal investigator | $3,544,545.63 | 69 |
| PY2021 | Principal investigator | $3,255,137.11 | 46 |
| PY2020 | Principal investigator | $1,576,434.72 | 37 |
| PY2019 | Principal investigator | $842,078.21 | 35 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
59 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Janssen Research & Development, LLC | $2,454.00 | 12/29/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1175440146 |
| Principal investigator 1 | Janssen Research & Development, LLC | $17,894.69 | 12/26/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy. | No dispute reported | 06/30/2026 | 1175440319 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,870.12 | 12/26/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy. | No dispute reported | 06/30/2026 | 1175440563 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,619.00 | 12/18/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | A Phase 1 First In Human Open Label Dose Escalation Study of JNJ64407564 a Humanized GPRC5D x CD3 DuoBody Antibody in Subjects with Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1175440140 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,132.00 | 12/15/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1175440434 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,033.41 | 12/11/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy. | No dispute reported | 06/30/2026 | 1175440900 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,071.85 | 12/08/2025 | Non-covered Recipient Entity HOPE FOUNDATION FOR CANCER RESEARCH | Phase III Study of DaratumumabrHuPH20 NSC 810307 + Lenalidomide or Lenalidomide as Post Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma MM Using Minimal Residual Disease to Direct Therapy Duration DRAMMATIC Study. | No dispute reported | 06/30/2026 | 1175402043 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,270.00 | 12/01/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1175440176 |
| Principal investigator 1 | Janssen Research & Development, LLC | $32,034.00 | 12/01/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1175440611 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,757.83 | 11/10/2025 | Non-covered Recipient Entity HOPE FOUNDATION FOR CANCER RESEARCH | Phase III Study of DaratumumabrHuPH20 NSC 810307 + Lenalidomide or Lenalidomide as Post Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma MM Using Minimal Residual Disease to Direct Therapy Duration DRAMMATIC Study. | No dispute reported | 06/30/2026 | 1175402060 |
| Principal investigator 1 | Janssen Research & Development, LLC | $943.00 | 11/03/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy. | No dispute reported | 06/30/2026 | 1175440368 |
| Principal investigator 1 | Janssen Research & Development, LLC | $26,141.32 | 10/31/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy. | No dispute reported | 06/30/2026 | 1175440829 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $6,047.46 | 10/29/2025 | Covered Recipient Teaching Hospital CITY OF HOPE NATIONAL MEDICAL CTR | AN OPEN-LABEL, MULTICENTER PHASE 1B STUDY INVESTIGATING THE SAFETY OF TAK-079 IN COMBINATION WITH BACKBONE REGIMENS FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AND FOR WHOM STEM CELL TRANSPLANTATION IS NOT PLANNED AS INITIAL THERAPY | No dispute reported | 06/30/2026 | 1223264982 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,228.00 | 10/24/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1175440311 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,929.43 | 10/13/2025 | Non-covered Recipient Entity HOPE FOUNDATION FOR CANCER RESEARCH | Phase III Study of DaratumumabrHuPH20 NSC 810307 + Lenalidomide or Lenalidomide as Post Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma MM Using Minimal Residual Disease to Direct Therapy Duration DRAMMATIC Study. | No dispute reported | 06/30/2026 | 1175402104 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,209.49 | 10/08/2025 | Covered Recipient Teaching Hospital CITY OF HOPE NATIONAL MEDICAL CTR | AN OPEN-LABEL, MULTICENTER PHASE 1B STUDY INVESTIGATING THE SAFETY OF TAK-079 IN COMBINATION WITH BACKBONE REGIMENS FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AND FOR WHOM STEM CELL TRANSPLANTATION IS NOT PLANNED AS INITIAL THERAPY | No dispute reported | 06/30/2026 | 1223264980 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,816.00 | 10/02/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1175440018 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,228.00 | 09/26/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1175440534 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,065.00 | 09/22/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1175440295 |
| Principal investigator 1 | Genentech, Inc. | $2,660.40 | 09/17/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | Ph I of FcRH5 CD3 in multiple myeloma | No dispute reported | 06/30/2026 | 1211533056 |
| Principal investigator 1 | Genentech, Inc. | $44,123.40 | 09/17/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | Ph I of FcRH5 CD3 in multiple myeloma | No dispute reported | 06/30/2026 | 1211533060 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,512.00 | 09/15/2025 | Non-covered Recipient Entity HOPE FOUNDATION FOR CANCER RESEARCH | Phase III Study of DaratumumabrHuPH20 NSC 810307 + Lenalidomide or Lenalidomide as Post Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma MM Using Minimal Residual Disease to Direct Therapy Duration DRAMMATIC Study. | No dispute reported | 06/30/2026 | 1175402078 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,576.00 | 08/28/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1175440249 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,180.00 | 08/28/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1175440587 |
| Principal investigator 1 | Janssen Research & Development, LLC | $37,500.00 | 08/11/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or | No dispute reported | 06/30/2026 | 1175440123 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200,046.89 | 08/08/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for the Treatment of Subjects with Multiple Myeloma | No dispute reported | 06/30/2026 | 1175440772 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,786.83 | 08/06/2025 | Non-covered Recipient Entity HOPE FOUNDATION FOR CANCER RESEARCH | Phase III Study of DaratumumabrHuPH20 NSC 810307 + Lenalidomide or Lenalidomide as Post Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma MM Using Minimal Residual Disease to Direct Therapy Duration DRAMMATIC Study. | No dispute reported | 06/30/2026 | 1175402027 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,205.00 | 08/04/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1175440331 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,699.00 | 07/24/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1175440106 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,456.00 | 07/24/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1175440622 |
| Principal investigator 1 | Janssen Research & Development, LLC | $464.39 | 07/11/2025 | Non-covered Recipient Entity HOPE FOUNDATION FOR CANCER RESEARCH | Phase III Study of DaratumumabrHuPH20 NSC 810307 + Lenalidomide or Lenalidomide as Post Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma MM Using Minimal Residual Disease to Direct Therapy Duration DRAMMATIC Study. | No dispute reported | 06/30/2026 | 1175402098 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,228.00 | 06/26/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1175440473 |
| Principal investigator 1 | Janssen Research & Development, LLC | $797.00 | 06/26/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1175440487 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $10,887.50 | 06/09/2025 | Non-covered Recipient Entity HRCE CORP | A PHASE III, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1192144787 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,245.76 | 06/09/2025 | Non-covered Recipient Entity HOPE FOUNDATION FOR CANCER RESEARCH | Phase III Study of DaratumumabrHuPH20 NSC 810307 + Lenalidomide or Lenalidomide as Post Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma MM Using Minimal Residual Disease to Direct Therapy Duration DRAMMATIC Study. | No dispute reported | 06/30/2026 | 1175402116 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $8,466.44 | 06/04/2025 | Covered Recipient Teaching Hospital CITY OF HOPE NATIONAL MEDICAL CTR | AN OPEN-LABEL, MULTICENTER PHASE 1B STUDY INVESTIGATING THE SAFETY OF TAK-079 IN COMBINATION WITH BACKBONE REGIMENS FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AND FOR WHOM STEM CELL TRANSPLANTATION IS NOT PLANNED AS INITIAL THERAPY | No dispute reported | 06/30/2026 | 1223264930 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,152.00 | 05/22/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1175440325 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,456.00 | 05/22/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1175440755 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,346.24 | 05/15/2025 | Non-covered Recipient Entity HOPE FOUNDATION FOR CANCER RESEARCH | Phase III Study of DaratumumabrHuPH20 NSC 810307 + Lenalidomide or Lenalidomide as Post Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma MM Using Minimal Residual Disease to Direct Therapy Duration DRAMMATIC Study. | No dispute reported | 06/30/2026 | 1175402054 |
| Principal investigator 1 | Janssen Research & Development, LLC | $47,613.00 | 05/12/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1175440736 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,285.58 | 04/11/2025 | Non-covered Recipient Entity HOPE FOUNDATION FOR CANCER RESEARCH | Phase III Study of DaratumumabrHuPH20 NSC 810307 + Lenalidomide or Lenalidomide as Post Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma MM Using Minimal Residual Disease to Direct Therapy Duration DRAMMATIC Study. | No dispute reported | 06/30/2026 | 1175402071 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,706.00 | 04/11/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for the Treatment of Subjects with Multiple Myeloma | No dispute reported | 06/30/2026 | 1175440720 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,064.00 | 03/31/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | A Phase 1 First In Human Open Label Dose Escalation Study of JNJ64407564 a Humanized GPRC5D x CD3 DuoBody Antibody in Subjects with Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1175440580 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,228.00 | 03/24/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1175440479 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,952.99 | 03/14/2025 | Non-covered Recipient Entity HOPE FOUNDATION FOR CANCER RESEARCH | Phase III Study of DaratumumabrHuPH20 NSC 810307 + Lenalidomide or Lenalidomide as Post Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma MM Using Minimal Residual Disease to Direct Therapy Duration DRAMMATIC Study. | No dispute reported | 06/30/2026 | 1175402038 |
| Principal investigator 1 | Genentech, Inc. | $313.20 | 03/05/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | Ph I of FcRH5 CD3 in multiple myeloma | No dispute reported | 06/30/2026 | 1211533053 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $178,281.58 | 02/21/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | A Modular Phase I IIOpenlabelMulticenterStudytoEvaluatetheSafetyTolerabilityPharmacokineticsImmunogenicityPharmacodynamicsandPreliminaryEfficacyofAZD0305asMonotherapyorinCombinationwithAnticancerAgentinParticipantswithRelapsedorRefractoryMultipleMyeloma | No dispute reported | 06/30/2026 | 1185539379 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,380.00 | 02/20/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1175440088 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,020.00 | 02/20/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1175440336 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,342.04 | 02/17/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for the Treatment of Subjects with Multiple Myeloma | No dispute reported | 06/30/2026 | 1175440862 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,911.35 | 02/13/2025 | Non-covered Recipient Entity HOPE FOUNDATION FOR CANCER RESEARCH | Phase III Study of DaratumumabrHuPH20 NSC 810307 + Lenalidomide or Lenalidomide as Post Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma MM Using Minimal Residual Disease to Direct Therapy Duration DRAMMATIC Study. | No dispute reported | 06/30/2026 | 1175402091 |
| Principal investigator 1 | Janssen Research & Development, LLC | $25,158.00 | 02/06/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | A Phase 1 First In Human Open Label Dose Escalation Study of JNJ64407564 a Humanized GPRC5D x CD3 DuoBody Antibody in Subjects with Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1175440157 |
| Principal investigator 1 | Janssen Research & Development, LLC | $488.00 | 01/23/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1175440568 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,523.24 | 01/16/2025 | Non-covered Recipient Entity HOPE FOUNDATION FOR CANCER RESEARCH | Phase III Study of DaratumumabrHuPH20 NSC 810307 + Lenalidomide or Lenalidomide as Post Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma MM Using Minimal Residual Disease to Direct Therapy Duration DRAMMATIC Study. | No dispute reported | 06/30/2026 | 1175402033 |
| Principal investigator 1 | Janssen Research & Development, LLC | $50,825.48 | 01/13/2025 | Non-covered Recipient Entity THE MULTIPLE MYELOMA RESEARCH CONSO RTIUM LLC | A Multi Center Open label Single Arm Phase II study of Daratumumab as Consolidation Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma | No dispute reported | 06/30/2026 | 1175377630 |
| Principal investigator 1 | Janssen Research & Development, LLC | $514.73 | 01/13/2025 | Non-covered Recipient Entity THE MULTIPLE MYELOMA RESEARCH CONSO RTIUM LLC | A Multi Center Open label Single Arm Phase II study of Daratumumab as Consolidation Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma | No dispute reported | 06/30/2026 | 1175377654 |
| Principal investigator 1 | Janssen Research & Development, LLC | $62,147.15 | 01/13/2025 | Non-covered Recipient Entity THE MULTIPLE MYELOMA RESEARCH CONSO RTIUM LLC | A Multi Center Open label Single Arm Phase II study of Daratumumab as Consolidation Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma | No dispute reported | 06/30/2026 | 1175377679 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,000.00 | 01/03/2025 | Covered Recipient Teaching Hospital CITY OF HOPE NATIONAL MEDICAL CTR | AN OPEN-LABEL, MULTICENTER PHASE 1B STUDY INVESTIGATING THE SAFETY OF TAK-079 IN COMBINATION WITH BACKBONE REGIMENS FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AND FOR WHOM STEM CELL TRANSPLANTATION IS NOT PLANNED AS INITIAL THERAPY | No dispute reported | 06/30/2026 | 1223264904 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,000.00 | 01/03/2025 | Covered Recipient Teaching Hospital CITY OF HOPE NATIONAL MEDICAL CTR | AN OPEN-LABEL, MULTICENTER PHASE 1B STUDY INVESTIGATING THE SAFETY OF TAK-079 IN COMBINATION WITH BACKBONE REGIMENS FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AND FOR WHOM STEM CELL TRANSPLANTATION IS NOT PLANNED AS INITIAL THERAPY | No dispute reported | 06/30/2026 | 1223264906 |